Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Esperion Therapeutics Trading Up 2.5 %

Esperion Therapeutics stock opened at $2.09 on Wednesday. The firm has a market capitalization of $395.85 million, a P/E ratio of -0.99 and a beta of 0.89. The stock has a fifty day moving average price of $2.30 and a 200 day moving average price of $2.07. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. As a group, equities analysts predict that Esperion Therapeutics will post -0.68 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC acquired a new position in shares of Esperion Therapeutics during the third quarter worth about $29,000. Jacob Asset Management of New York LLC acquired a new stake in Esperion Therapeutics in the third quarter valued at approximately $59,000. Monaco Asset Management SAM raised its stake in shares of Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 476,477 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Esperion Therapeutics during the third quarter worth $131,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Esperion Therapeutics by 120.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 225,767 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.